Cardiovascular Outcome in T2D Patients: A Real World Evidence Study of the Effectiveness of SGLT2 Inhibitors and GLP1-RA

Read full text Summarise with VIRAT
Authors: Salah Abusnana, Shoq M. Alhomaidhan, Bashair M. Mussa, Rawoof Khan
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: Individuals with T2D face increased cardiovascular risk. Clinical trials show SGLT2i and GLP1-RA improve glycemic control and reduce cardiovascular events and heart failure hospitalizations. Objective: The study aims to determine whether real-world evidence supports clinical trial findings that the use of SGLT2i and GLP1-RA reduces the incidence of heart failure, stroke, ischemic heart disease, and the hospitalization rate among T2D in comparison with standard treatments. Methods: A retrospective cohort study of 270 T2D patients from December 2023 at the University Hospital of Sharjah endocrine clinic was conducted. Patients over 18 on anti-diabetic medications for at least 3 months were included. Those with irregular follow-ups, recent T2D diagnosis, or nondiabetic obesity were excluded. Patients were grouped into new treatment (GLP-1 RA, SGLT2-i) and standard treatment groups. Results: Among 270 patients, the gender distribution was nearly equal, with 49.1% females and 50.6% males, and the majority (66.1%) were Emiratis. The participants were 52 years old on average, dyslipidemia was present in 73.2%, cardiovascular disease in 23.3%, and obesity in 79.3%, with a mean BMI of over 31 kg/m 2 . Glycemic control was poor among the majority, as evidenced by a mean HbA1c of 9.56%. In terms of medication usage, SGLT2 inhibitors were the most prescribed (61.1%), often combined with metformin. Hospitalizations occurred in 8.9% of participants, ischemic heart disease in 7%, and myocardial infarction in 5.6%. GLP1-RA had a statistically significant effect on reducing myocardial infarctions and hospitalizations. DPP4-i, when combined with GLP1-RA, reduced hypertension significantly. Metformin had a near-significant effect on hospitalization rates. Conclusion: New antidiabetic medications, SGLT2 inhibitors and GLP1 receptor agonists, have been shown to improve cardiovascular outcomes, which is critical for effective diabetes treatment. Future research could benefit from larger and more diverse prospective cohort studies that take into account variables such as diet, exercise, medication dosages, and diabetes duration. Publication History Article published online: 25 March 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

Fields of Study & Subjects

Diabetes Treatment and Management Heart Failure Treatment and Management Diabetes Cardiovascular Risks and Lipoproteins

Publication details

Journal / source
Ibnosina Journal of Medicine and Biomedical Sciences
Volume
18
Publication date
1 March 2026
Language
EN